Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa

Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa

Resumen: Introducción y objetivo: La hepatitis C crónica es de las principales causas de cirrosis hepática. El tratamiento con antivirales de acción directa (AAD) mejora la supervivencia. Existe controversia si los AAD generan un incremento del riesgo para desarrollar carcinoma hepatocelular (CHC)....

Full description

Bibliographic Details
Main Authors:	I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar
Format:	Article
Language:	Spanish
Published:	Elsevier 2022-10-01
Series:	Revista de Gastroenterología de México
Subjects:	Chronic hepatitis C Direct-acting antivirals Hepatocellular carcinoma
Online Access:	http://www.sciencedirect.com/science/article/pii/S0375090621001269

Similar Items

Comportamiento virológico de pacientes con hepatitis C tratados con antivirales cubanos
by: Sahilí Corrales Alonso, et al.

Coste y efectividad de los nuevos antivirales para la hepatitis C.
by: Sabela Lens, et al.
Published: (2015-10-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
by: Tatsuya Minami, et al.
Published: (2021-06-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
by: Cassia Leal, et al.
Published: (2023-01-01)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
by: Eiichi Ogawa, et al.
Published: (2020-09-01)

Direct-acting antivirals: a new strategy in the treatment of hepatitis C virus infection in patients with cirrhosis
by: Mariana Avricenco
Published: (2019-12-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Actuación de enfermería ante un paciente con infección aguda por el virus de la hepatitis C en hemodiálisis en tratamiento con antivirales de acción directa
by: Antonio López González, et al.
Published: (2017-12-01)

Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence
by: Ciro Celsa, et al.
Published: (2022-01-01)

Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
by: Ming‐Lun Yeh, et al.
Published: (2021-02-01)

Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct‐acting antivirals
by: Satoshi Takakusagi, et al.
Published: (2021-01-01)

Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves
by: El Kassas M, et al.
Published: (2019-11-01)

Evaluación económica de una estrategia poblacional de tratamiento de la hepatitis C crónica con antivirales de acción directa
by: Javier Mar, et al.
Published: (2018-10-01)

Efectividad del tratamiento con agentes antivirales directos en pacientes con coinfección por VHC y VIH. Estudio de cohorte multicéntrico
by: David Rial-Crestelo, et al.

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
by: Ryoko Kuromatsu, et al.
Published: (2022-05-01)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
by: Naoki Kawagishi, et al.
Published: (2023-01-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan
by: Yukiyasu Okamura, et al.
Published: (2021-07-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
by: Toshifumi Tada, et al.
Published: (2022-01-01)

Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review
by: Lorenzo Lani, et al.
Published: (2024-02-01)

Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014–2020
by: Justin Chan, MD, et al.
Published: (2024-04-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
by: Kwang Il Seo, et al.
Published: (2017-03-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-10-01)

Clinical impact of normal alanine aminotransferase on direct‐acting antiviral outcome in patients with chronic hepatitis C virus infection
by: Satoru Joshita, et al.
Published: (2020-08-01)

Carcinoma hepatocelular: parte 2. Tratamento Hepatocelular carcinoma: part 2. Therapy
by: Vinício Paride CONTE
Published: (2000-04-01)

Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus
by: Shuling Wu, et al.
Published: (2023-01-01)

Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis
by: D T Abdurakhmanov
Published: (2013-10-01)

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
by: Tom Domovitz, et al.
Published: (2021-02-01)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor
by: Leona Osawa, et al.
Published: (2020-05-01)

Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs
by: Martynas Ridziauskas, et al.
Published: (2021-02-01)

Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR
by: Zou Y, et al.
Published: (2022-12-01)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
by: Taisuke Imamura, et al.
Published: (2022-04-01)

Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations
by: Carolina Delgado Martínez, et al.
Published: (2021-03-01)